Central Trust Company’s AtriCure ATRC Stock Holding History

Central Trust Company’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-35	Closed	-$1.15K	–	1420
2025 Q2	$1.15K	Hold	35	–	–	﹤0.01%	1358
2025 Q1	$1.13K	Hold	35	–	–	﹤0.01%	1373
2024 Q4	$1.07K	Hold	35	–	–	﹤0.01%	1378
2024 Q3	$982	Hold	35	–	–	﹤0.01%	1320
2024 Q2	$797	Hold	35	–	–	﹤0.01%	1353
2024 Q1	$1.06K	Hold	35	–	–	﹤0.01%	1314
2023 Q4	$1.25K	Sell	35 -297	-89%	-$11K	﹤0.01%	1315
2023 Q3	$14.5K	Buy	332 +35	+12%	+$1.71K	﹤0.01%	983
2023 Q2	$14.7K	Hold	297	–	–	﹤0.01%	978
2023 Q1	$12.3K	Hold	297	–	–	﹤0.01%	1020
2022 Q4	$13.2K	Hold	297	–	–	﹤0.01%	978
2022 Q3	$12K	Sell	297 -14	-5%	-$640	﹤0.01%	1005
2022 Q2	$13K	Hold	311	–	–	﹤0.01%	1002
2022 Q1	$20K	Buy	311 +14	+5%	+$907	﹤0.01%	949
2021 Q4	$21K	Hold	297	–	–	﹤0.01%	937
2021 Q3	$21K	Hold	297	–	–	﹤0.01%	910
2021 Q2	$24K	Buy	+297	New	+$21.6K	﹤0.01%	850

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Central Trust Company's ATRC Position: Q3 2025 in Review

Central Trust Company sold out of AtriCure (ATRC) in Q3 2025, closing a stake of 35 shares — an estimated $1.15K sold.

Central Trust Company first reported a position in ATRC in Q2 2021 and held it in 17 quarters. The position peaked at $24K in Q2 2021. 223 funds tracked by Wall St. Rank hold ATRC as of Q3 2025.

Central Trust Company reported no remaining AtriCure position as of Q3 2025 after selling out during the quarter.
Central Trust Company sold 35 AtriCure shares in Q3 2025, an estimated $1.15K.
Central Trust Company first reported a position in AtriCure in Q2 2021 and held it in 17 quarters.
Central Trust Company's AtriCure position peaked at $24K in Q2 2021.
223 funds tracked by Wall St. Rank held AtriCure as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.